IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER

Stage IIIB Gallbladder Cancer AJCC v7

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Dormant

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

30 Active assets in the Stage IIIB Gallbladder Cancer AJCC v7 cohort.

Asset / Sponsor	Phase	Rating
Eloxatin Lisata Therapeutics, Inc.	Phase 2	B
FLUOROURACILUM Lisata Therapeutics, Inc.	Phase 2	B
CIS-DIAMMINEDICHLOROPLATINUM II Lisata Therapeutics, Inc.	Phase 2	B
Durvalumab Lisata Therapeutics, Inc.	Phase 2	B
Pembrolizumab Seagen, a wholly owned subsidiary of Pfizer	Phase 2	B

View all 36 →

Same molecule, other indications

IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER is also rated in:

urothelial carcinomaDormant

Indicative ·

68 / 100

View asset →

hepatocellular carcinomaDormant

Indicative ·

65 / 100

View asset →

lung cancerDormant

Indicative ·

64 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →